BDTXBlack Diamond Therapeutics
About Black Diamond Therapeutics
Black Diamond Therapeutics (NASDAQ:BDTX) is a biotechnology firm dedicated to discovering and developing precision medicines for cancer patients. With a focus on addressing genetically defined diseases driven by oncogenes, the company leverages its proprietary technology platform to target and inhibit elusive cancer-driving proteins. Black Diamond Therapeutics aims to unveil new treatment options for patients with limited or no existing therapeutic avenues, emphasizing a commitment to innovation and patient care in the oncology sector.
What is BDTX known for?
Snapshot
Public US
Ownership
2014
Year founded
54
Employees
Cambridge, United States
Head office
1 of 1
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
Newton, US
Products and/or services of Black Diamond Therapeutics
- Development of BDTX-1535, a targeted therapy for lung and brain cancers with specific genetic mutations.
- Creation of a platform for discovering MasterKey therapies for genetically defined cancers.
- Research on a new class of small molecule therapies designed to target allosteric mutations across multiple cancer types.
- Development of diagnostic tools to identify patients who could benefit from their MasterKey therapies.
Black Diamond Therapeutics executive team
- Dr. Mark A. Velleca M.D., Ph.D.CEO, President & Chairman
- Mr. Brent Hatzis-Schoch Esq., J.D.COO & General Counsel
- Dr. Sergey Yurasov M.D., Ph.D.Chief Medical Officer
- Dr. Elizabeth Buck Ph.D.Co-Founder & Chief Scientific Officer
- Ms. Erika JonesPrincipal Financial Officer, Principal Accounting Officer, SVP of Finance & Corporate Controller
- Ms. Melanie MorrisonChief Development Officer